Novartis, Monte Rosa strike $5.7 billion drug development deal
15/09/2025 12:11
Sept 15 (Reuters) - Swiss drugmaker Novartis NOVN.S and drug developer Monte Rosa Therapeutics GLUE.O signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. (Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million